AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2068468
Drug: Clindamycin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (600 mg) plus aztreonam (1 g)
Trial: 2068468
Drug: Clindamycin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (600 mg) plus gentamicin (80 mg)
Trial: 7048482
Drug: Aspirin +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin + Dipyridamole
Trial: 31286694
Drug: Nasal high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high flow (NHF) at 2, 4, and 6 L/min
Trial: 26022434
Drug: RCA plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCA plus low-dose dalteparin
Trial: 26022434
Drug: Normal-dose dalteparin
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-dose dalteparin
Trial: 26022434
Drug: RCA only,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCA only, Normal-dose dalteparin
Trial: 17478880
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied heparin spraygel
Trial: 17478880
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (peroral analgesics or nonsteroidal anti‐inflammatory drugs, elastic stockings, mild ambulation)
Trial: 12815777
Drug: Mivacron (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacron (0.15 mg/kg)
Trial: 12815777
Drug: Mivacron (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacron (0.1 mg/kg)
Trial: 9274466
Drug: sucralfate 1
RxNorm normalized name: sucralfate 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sucralfate 1 g four times daily
Trial: 9274466
Drug: sucralfate 2
RxNorm normalized name: sucralfate 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sucralfate 2 g twice daily
Trial: 8391041
Drug: Post-therapy liver
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-therapy liver biopsy
Trial: 24262498
Drug: Polidocanol (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polidocanol (1, 3, or 4 ml depending on hydrocele size) after aspiration
Trial: 22313070
Drug: lignocaine added
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lignocaine added to infiltrating solution
Trial: 20089522
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate (3.75 mg, depot i.m. injection, every 4 weeks)
Trial: 18453852
Drug: Lopinavir/ritonavir tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir tablets (600/150 mg or 800/200 mg twice daily) with 600 mg rifampicin once daily
Trial: 15753741
Drug: 4 ng/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ng/kg intravenous Escherichia coli endotoxin
Trial: 7437237
Drug: Indoramin 75
RxNorm normalized name: indoramin
DrugBank: Indoramin (DB08950)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin 75 mg twice daily
Trial: 12165596
Drug: Oral 30%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 30% glucose (0.3 mL)
Trial: 12165596
Drug: Placebo (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.3 mL of sterile water)
Trial: 12165596
Drug: Oral 30%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 30% glucose (0.3 mL) plus pacifier
Trial: 6760120
Drug: Both types
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both types of insulin therapy
Trial: 31701593
Drug: Minimally interrupted
RxNorm normalized name: homatropine hydrobromide Ophthalmic Solution [Minims Homatropine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally interrupted direct oral anticoagulation (DOAC) therapy
Trial: 31701593
Drug: Uninterrupted direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uninterrupted direct oral anticoagulation (DOAC) therapy
Trial: 27317706
Drug: Sumatriptan (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (6 mg s.c. injection)
Trial: 22709272
Drug: 5% nicotinamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% nicotinamide lotion
Trial: 22709272
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg oral nicotinamide
Trial: 15732070
Drug: Fluoxetine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine with guided self-help
Trial: 15732070
Drug: Fluoxetine without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine without guided self-help
Trial: 7594660
Drug: Ro 24-7429
RxNorm normalized name: Ro 24-7429
DrugBank: Ro 24-7429 (DB16062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 24-7429 (Tat antagonist) at 75, 150, or 300 mg/day
Trial: 314399
Drug: Enelbin‐Rheuma‐ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enelbin‐Rheuma‐ointment
Trial: 30169322
Drug: Low-exposure everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Low-exposure everolimus (3-7 ng/mL)
Trial: 30169322
Drug: High-exposure everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: High-exposure everolimus (9-15 ng/mL)
Trial: 30169322
Drug: Everolimus (3-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (3-15 ng/mL) during extension phase
Trial: 27694157
Drug: Topotecan (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (1.5 mg/m2 intravenously or 2.3 mg/m2 orally, daily for 5 days for 4 cycles)
Trial: 27694157
Drug: Linsitinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linsitinib (150 mg orally twice daily until progression)
Trial: 19086108
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) with oestradiol and noretisterone acetate, vitamin D3 and calcium
Trial: 12600843
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g high-performance inulin/d
Trial: 8407216
Drug: Levodopa/carbidopa 25/6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/carbidopa 25/6.25 mg
Trial: 8407216
Drug: Levodopa/carbidopa 50/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/carbidopa 50/12.5 mg
Trial: 3940504
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (300 mg orally) with zinc sulfate
Trial: 3940504
Drug: Aluminum hydroxide
RxNorm normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aluminum hydroxide (30 mL orally) with zinc sulfate
Trial: 27602929
Drug: Self-prepared, 1-day,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-prepared, 1-day, low-residue diets with a same-day 2.0-L single-dose of polyethylene glycol (Group A)
Trial: 27602929
Drug: Prepackaged low-residue
RxNorm normalized name: hydroxypropyl betadex (0.6 hydroxypropyl residues per glucose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prepackaged low-residue diets plus 2.0 L of polyethylene glycol (Group B)
Trial: 27602929
Drug: Prepackaged low-residue
RxNorm normalized name: hydroxypropyl betadex (0.6 hydroxypropyl residues per glucose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prepackaged low-residue diets plus 1.5 L of polyethylene glycol (Group C)
Trial: 23506436
Drug: Ice slurry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice slurry ingestion (10 g · kgBM(‐1) of ice slurry < 1°C)
Trial: 9275430
Drug: Tumor infiltrating
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor infiltrating lymphocytes (TIL) and chemotherapy
Trial: 29995356
Drug: Withania somnifera
RxNorm normalized name: WITHANIA SOMNIFERA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withania somnifera extract (WSE) 1,000 mg/d
Trial: 27580669
Drug: Physiotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy and Occupational Therapy (PT and OT) NHS services, n=381
Trial: 27580669
Drug: No therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy, n=381
Trial: 20142595
Drug: Single subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single subcutaneous pegfilgrastim injection (100 microg/kg)
Trial: 20142595
Drug: Daily subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous filgrastim administration (5 microg/kg)
Trial: 16563271
Drug: Xuezhikang (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang (0.6 g, Bid)
Trial: 12372764
Drug: DDAVP +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDAVP + low-calcium diet (approximately 500 mg/day) for 3-6 months in hypercalciuric patients
Trial: 12372764
Drug: Low-calcium diet
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-calcium diet (approximately 500 mg/day) for 3-6 months in hypercalciuric patients
Trial: 1431364
Drug: Cefepime (CFPM)
DrugBank: Cefepime (DB01413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefepime (CFPM) 1.0 g twice daily for 14 days
Trial: 1431364
Drug: Ceftazidime (CAZ)
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime (CAZ) 1.0 g twice daily for 14 days
Trial: 20921836
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type-A (BTX-A) injection
Trial: 20921836
Drug: Control drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control drug (NaCl 0.9% or bupivacaine 0.25%)
Trial: 16083067
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose MNZ (2 g daily for 7 days)
Trial: 16083067
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg N‐9 vaginal suppository daily for 7 days
Trial: 16083067
Drug: Conventional MNZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional MNZ dose (1 g daily for 7 days) plus 100 mg N‐9 suppository for 7 days
Trial: 9316695
Drug: L-DOPA (LD)
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: L-DOPA (LD) treatment
Trial: 3354990
Drug: Indomethacin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (25 mg four times a day for 7 doses)
Trial: 29327644
Drug: PREHAB+ (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PREHAB+ (once weekly supervised prehabilitation)
Trial: 27064347
Drug: Body Psychotherapy/Dance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body Psychotherapy/Dance Movement Therapy (BPT/DMT) - 20 sessions
Trial: 22938573
Drug: 6 mm
RxNorm normalized name: I-Port, 6 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mm implants
Trial: 22938573
Drug: 11 mm
RxNorm normalized name: Interleukin 11
DrugBank: Oprelvekin (DB00038)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 11 mm implants
Trial: 20031783
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary intervention (PCI) plus optimal medical therapy
Trial: 10944126
Drug: LV5FU2 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LV5FU2 plus oxaliplatin (200 mg/m2/d leucovorin, 400 mg/m2/d bolus 5FU, 600 mg/m2/d infusional 5FU for 2 days every 2 weeks, plus 85 mg/m2 oxaliplatin on day 1)
Trial: 10944126
Drug: LV5FU2 alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LV5FU2 alone (200 mg/m2/d leucovorin, 400 mg/m2/d bolus 5FU, 600 mg/m2/d infusional 5FU for 2 days every 2 weeks)
Trial: 8746336
Drug: Topical calcitriol
RxNorm normalized name: calcitriol Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical calcitriol (1.5 micrograms per day, 15 micrograms/g of Vaseline)
Trial: 8746336
Drug: Topical calcitriol
RxNorm normalized name: calcitriol Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical calcitriol ointment (15 micrograms/g Vaseline) applied to all lesions (up to 10 g, 150 micrograms calcitriol)
Trial: 20510549
Drug: Heroin Assisted
RxNorm normalized name: heroin
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heroin Assisted Treatment (HAT)
Trial: 20510549
Drug: Optimized Methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized Methadone Maintenance Treatment (MMT)
Trial: 8543957
Drug: Manufacturer and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manufacturer and brand of L-tryptophan
Trial: 1791086
Drug: Single-dose verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose verapamil (120 mg)
Trial: 1791086
Drug: Seven-doses of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seven-doses of verapamil (120 mg thrice daily)
Trial: 6780258
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (NTG) treatment for 48 hours
Trial: 25623343
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for insomnia (CBT-I), 8 sessions
Trial: 10783015
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation (60 mg of retinol as retinyl palmitate) during acute diarrhea
Trial: 10783015
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin A supplementation (60 mg of retinol as retinyl palmitate) after resolution of diarrhea
Trial: 8803503
Drug: L-carnitine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine supplementation (2 g, administered 2 hours before and after 20 km of the marathon)
Trial: 1615614
Drug: Doxorubicin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (20 mg/m2 body surface area)
Trial: 6235140
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) 20 mg twice daily
Trial: 6235140
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) 1 g/wk intramuscularly
Trial: 6235140
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (TAM and MPA)
Trial: 18962989
Drug: EPA 2
RxNorm normalized name: docosahexaenoic acid/epa 250 mg-100 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA 2 g/day
Trial: 4054194
Drug: Metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol 100 mg b.d. (twice daily)
Trial: 30135541
Drug: Iterative model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iterative model reconstruction (IMR) with 80 kV/30 ml contrast media
Trial: 30135541
Drug: Filtered back
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Filtered back projection (FBP) with 100 kV/50 ml contrast media
Trial: 25363127
Drug: triamcinolone 0.5
RxNorm normalized name: triamcinolone 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triamcinolone 0.5 mL with lidocaine 2%
Trial: 20375984
Drug: SBR759 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBR759 at 11.25 g/day
Trial: 20375984
Drug: SBR759 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBR759 at 15.0 g/day
Trial: 20375984
Drug: SBR759 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBR759 at 3.75-15 g/day
Trial: 18599797
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens 0.625 mg with medroxyprogesterone acetate 2.5 mg daily
Trial: 18599797
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens 0.625 mg daily
Trial: 12887173
Drug: Duac Topical
RxNorm normalized name: Duac Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duac Topical Gel (clindamycin 1%‐benzoyl peroxide 5%)
Trial: 1299794
Drug: glucose solution
RxNorm normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: glucose solution (placebo)
Trial: 30811685
Drug: High postural
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High postural sway (highest quartile of ML sway)
Trial: 30811685
Drug: High postural
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High postural sway (fourth quartile of ML sway)
Trial: 30811685
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lowest bone density and highest postural sway
Trial: 31721467
Drug: Dapagliflozin 5
RxNorm normalized name: dapagliflozin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 5 mg/day for 24 weeks
Trial: 28460889
Drug: Olesoxime (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olesoxime (10 mg/kg per day)
Trial: 26507206
Drug: Usual medical
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual medical treatment (tranexamic acid, mefenamic acid, combined oestrogen-progestogen or progesterone alone)
Trial: 24037893
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with TPF regimen (docetaxel 75 mg/m(2), cisplatin 75 mg/m(2), and 5‐fluorouracil 2500 mg/m(2) every 3 weeks for 3 cycles) followed by concurrent chemoradiation (cisplatin 40 mg/m(2) per week with either 3-dimensional conformal radiation therapy or intensity-modulated radiation therapy)
Trial: 19517892
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (amisulpride 200 mg)
Trial: 19517892
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (amisulpride 200 mg)
Trial: 11447776
Drug: Intraarticular administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarticular administration of high molecular weight sodium hyaluronate (one 20 mg vial/week for 3 weeks)
Trial: 15512177
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate 10 mg daily
Trial: 7517472
Drug: Oral treatment
RxNorm normalized name: Other agents for local oral treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment with vasoactive compounds
Trial: 7517472
Drug: Long-term physical
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term physical exercise (twice for 2 h/week for 24 months)
Trial: 7517472
Drug: Intensive therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapeutic regimens using intravenous infusions
Trial: 23871729
Drug: G biloba
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G biloba
Trial: 16933577
Drug: Atorvastatin (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (Group 1)
Trial: 15152589
Drug: Epidural preemptive
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural preemptive analgesia with 2 micrograms/kg fentanyl in 0.25% bupivacaine in 10 ml serum saline
Trial: 15152589
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received 10 ml serum saline 20 minutes before the incision
Trial: 11310460
Drug: Intramuscular midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular midazolam (0.4 mg/kg)
Trial: 11310460
Drug: Intranasal flumazenil
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal flumazenil (25 microg/kg)
Trial: 11310460
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose intramuscular ketamine (2.5 mg/kg)
Trial: 3691913
Drug: Topical minoxidil
RxNorm normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical minoxidil (3% solution)
Trial: 3691913
Drug: Topical minoxidil
RxNorm normalized name: MINOXIDIL 50 mg in 1 mL TOPICAL SOLUTION [Stafenit Hair Regrowth Treatment Topical Minoxidil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical minoxidil (5% solution)